Longeveron Inc. (NASDAQ:LGVN) Surpasses Earnings and Revenue Estimates

Longeveron reported an EPS of -$0.23 for March 17, 2026, beating the estimated EPS of -$0.37, indicating a better-than-expected financial performance.The company's revenue reached $365,000, significantly exceeding the estimated revenue of $110,330, showcasing its ability to generate higher sales than anticipated.Longeveron is advancing its pivotal Phase 2b clinical trial, ELPIS II, for treating Hypoplastic Left Heart Syndrome (HLHS), with results expected in the third quarter of 2026, which could be a major ...